ArticleEuropean journal of clinical pharmacology2003
Efficacy, safety and cost of new drugs acting on the central nervous system.
Article in European journal of clinical pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A new approach to psychiatric drug approval in Europe.PLoS medicine · 2013Article
- Improving the prediction of the brain disposition for orally administered drugs using BDDCS.Advanced drug delivery reviews · 2012Review
- Does the development of new medicinal products in the European Union address global and regional health concerns?Population health metrics · 2010Article
- An update on the first decade of the European centralized procedure: how many innovative drugs?British journal of clinical pharmacology · 2006Article
- Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003.British journal of clinical pharmacology · 2005Article
- Risk:benefit assessment of old medicines.British journal of clinical pharmacology · 2004Review
- Efficacy, safety and cost of new cardiovascular drugs: a survey.European journal of clinical pharmacology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the degree of innovation of the products with indications for CNS diseases approved for the European market through the centralized procedure.
methodsThis paper examines the documentation available on nine products approved by the European Medicines Evaluation Agency in its first years of activity.
resultsThe Committee for Proprietary Medicinal Products approved only five products by consensus (levacetylmethadol, levetiracetam, olanzapine, pramipexole, riluzole). Four were approved by majority (entacapone, memantine, rivastigmine, zaleplon). One product received a negative opinion, and five had the application withdrawn before reaching the Committee decision.
conclusionsAn analysis of the efficacy and safety profile of these products indicates that few minor therapeutic advances have been achieved in this area. Most approved products cover needs already met, at higher cost, without substantial improvement.
Indexed as
Identifiers
12743674What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.